Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

42 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

dbGaP phs001244 Nasopharynx Cancer Whole Exome Sequencing - Eligibility

- 06-04-23 - 5 Formulieren, 1 Itemgroep, 1 Data-element, 1 Taal
Itemgroep: IG.elig
Principal Investigator: Kwok-wai Lo, Chinese University of Hong Kong, Hong Kong, China MeSH: Nasopharyngeal Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001244 Nasopharyngeal carcinoma (NPC) is an aggressive head and neck cancer characterized by Epstein-Barr virus (EBV) infection and dense lymphocyte infiltration. The scarcity of NPC genomic data hinders the understanding of NPC biology, disease progression, and rational therapy design. Here, we performed whole-exome sequencing (WES) on 111 micro-dissected EBV-positive NPCs, with 15 cases subjected to further whole-genome sequencing (WGS), to determine its mutational landscape. We identified enrichment for genomic aberrations of multiple negative regulators of the NF-kB pathway in a total of 41% of cases including CYLD, TRAF3, NFKBIA and NLRC5. Functional analysis confirmed novel inactivating CYLD mutations as drivers for NPC cell growth. The EBV oncoprotein latent member protein 1 (LMP1) functions to constitutively activate NF-kB signaling, and we observed mutual exclusivity among somatic NF-kB pathway aberrations and LMP1-overexpression, suggesting that NF-kB activation is selected for by both somatic and viral events during NPC pathogenesis.

pht006055.v1.p1

1 Itemgroep 2 Data-elementen

pht006056.v1.p1

1 Itemgroep 3 Data-elementen

pht006057.v1.p1

1 Itemgroep 13 Data-elementen

pht006058.v1.p1

1 Itemgroep 4 Data-elementen

Eligibility Nasopharyngeal Carcinoma NCT01271439

- 21-09-18 - 1 Formulier, 2 Itemgroepen, 21 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT01271439 Collaborating Parties: Zhejiang Cancer Hospital Wenzhou Medical University The First Affiliate Hospital of Guangxi Medical College Xijing Hospital Hunan Cancer Hospital Jiangxi Provincial Cancer Hospital Wuhan Union Hospital, China Wuhan University Hubei Cancer Hospital Tongji University Cancer Hospital of Shantou University Shenzhen People's Hospital First People's Hospital of Foshan

Eligibility Local Advanced High Risk Nasopharyngeal Carcinoma NCT02143388

- 30-06-20 - 1 Formulier, 2 Itemgroepen, 16 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Phase II Randomized Control Clinical Trial; ODM derived from: https://clinicaltrials.gov/show/NCT02143388

Eligibility Nasopharyngeal Carcinoma NCT00592501

- 01-06-17 - 1 Formulier, 2 Itemgroepen, 19 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00592501

Eligibility Nasopharyngeal Carcinoma NCT02363400

- 22-05-19 - 1 Formulier, 2 Itemgroepen, 19 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA; ODM derived from: https://clinicaltrials.gov/show/NCT02363400

Eligibility Nasopharyngeal Carcinoma NCT02512315

- 21-05-19 - 1 Formulier, 2 Itemgroepen, 13 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02512315

Eligibility Nasopharyngeal Carcinoma NCT02460419

- 21-05-19 - 1 Formulier, 2 Itemgroepen, 17 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02460419

Eligibility Nasopharyngeal Carcinoma NCT02016417

- 21-05-19 - 1 Formulier, 2 Itemgroepen, 16 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Induction Chemotherapy With GP Versus TPF in the Treatment of Advanced Nasopharyngeal Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02016417

Eligibility Nasopharyngeal Carcinoma NCT00953420

- 26-09-18 - 1 Formulier, 2 Itemgroepen, 18 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes; ODM derived from: https://clinicaltrials.gov/show/NCT00953420

Eligibility Nasopharyngeal Carcinoma NCT02501993

- 08-01-19 - 1 Formulier, 2 Itemgroepen, 9 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Nasopharyngeal Carcinoma Screening in Zhongshan City; ODM derived from: https://clinicaltrials.gov/show/NCT02501993

Eligibility Nasopharyngeal Carcinoma NCT02328261

- 08-01-19 - 1 Formulier, 2 Itemgroepen, 9 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02328261

Eligibility Nasopharyngeal Carcinoma NCT01417390

- 21-09-18 - 1 Formulier, 2 Itemgroepen, 13 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Study of Neoadjuvant Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT01417390

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial